Cytogenetic and Molecular Abnormalities in Hematologic Malignancies: A Comprehensive Review of Mechanisms,Biomarkers, and Therapeutic Advances
Keywords:
Cytogenetics, Hematologic malignancies, Leukemia, Lymphoma, Molecular biomarkers, Precision medicine, Targeted therapyAbstract
Cytogenetic and molecular abnormalities are fundamental drivers of hematologic malignancies, shaping disease classification, prognosis, and therapeutic decision-making. Over the past two decades, advances in next-generation sequencing and precision medicine have substantially expanded our understanding of the genetic and epigenetic mechanisms underlying leukemia, lymphoma, and related disorders. To provide a comprehensive synthesis, a narrative review of peer-reviewed literature published between January 2000 and June 2025 was conducted across PubMed, Scopus, Embase, and Web of Science. Eligible studies included original research, systematic reviews, and meta- analyses reporting on cytogenetic and molecular mechanisms, diagnostic biomarkers, and therapeutic innovations in hematologic malignancies. Findings from this review highlight recurrent chromosomal abnormalities such as t(9;22) BCR-ABL1 in chronic myeloid leukemia, t(15;17) PML-RARA in acute promyelocytic leukemia, and del(17p)/TP53 mutations in chronic lymphocytic leukemia as pivotal prognostic and therapeutic markers. Molecular mutations including FLT3, NPM1, IDH1/2, and DNMT3A were consistently linked to poor or intermediate outcomes in acute
myeloid leukemia, while MYD88 and EZH2 mutations were frequently observed in B-cell lymphomas. Diagnostic modalities such as fluorescence in situ hybridization, PCR, and next-generation sequencing were shown to improve classification and treatment guidance. Importantly, targeted therapies including tyrosine kinase inhibitors, FLT3 and IDH inhibitors, and epigenetic modulators have significantly transformed patient outcomes, although access and treatment resistance remain major barriers, especially in low-resource settings. This review underscores the need for molecularly informed diagnostic algorithms, wider integration of next-generation sequencing into standard care, and expanded access to targeted therapies. Strengthening laboratory infrastructure, establishing region-specific treatment guidelines, and enhancing equitable access to molecular testing and therapy are essential steps toward improving outcomes. Overall, cytogenetic and molecular profiling has redefined the management of hematologic malignancies, but disparities in access and the emergence of resistance highlight the importance of continued innovation, biomarker discovery, and personalized therapeutic strategies to achieve durable patient benefit.
References
1. WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Haematolymphoid Tumours. 5th ed. Lyon: IARC; 2022.
2. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719.
3. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290–293.
4. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
5. Behrens, Y. L., Pietzsch, S., Antić, Ž., Zhang, Y., & Bergmann, A. K. (2024). The landscape of cytogenetic and molecular genetic methods in diagnostics for hematologic neoplasia. Best Practice & Research Clinical Haematology, 37(1), 101539. https://doi.org/10.1016/j.beha.2024.101539
6. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with AML. Blood. 2019;133(1):7–17.
7. Daver, N., Wei, A. H., Pollyea, D. A., Fathi, A. T., Vyas, P., & DiNardo, C. D. (2020). New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer Journal, 10(10). https://doi.org/10.1038/s41408-020-00376-1
8. Obu, S. I., Dibigbo–Ibeaji, N., Obu, G. O., & Ilikannu, S. O. (2024). Diagnostic Challenges in Hematological Malignancies in Nigeria and their Impact on Treatment Outcome. International Blood Research & Reviews, 15(4), 8–15. https://doi.org/10.9734/ibrr/2024/v15i4345
9. de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10(11):775–783.
10. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations. Blood. 2017;129(4):424–447.
11. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol. 2008;87(7):515–526.
12. Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, et al. TP53 mutation and survival in CLL. Blood. 2010;115(22):4350–4357.
13. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758–764.
14. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152.
15. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed/refractory AML. N Engl J Med. 2018;378(25):2386–2398.
16. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for FLT3-mutated AML. N Engl J Med. 2017;377(5):454–464.
17. Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed/refractory AML. Blood. 2017;130(6):722–731.
18. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in AML. N Engl J Med. 2010;363(25):2424–2433.
19. Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122(24):3884–3891.
20. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell ALL. N Engl J Med. 2018;378(5):439–448.
21. Heim S, Mitelman F. Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells. 4th ed. Hoboken: Wiley-Blackwell; 2015.
22. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion transcripts in leukemia. Leukemia. 1999;13(12):1901–1928.
23. Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17–23.
24. Raza A, Galili N. The genetic basis of myelodysplastic syndromes. Semin Oncol. 2011;38(5):613–620.
25. Papaemmanuil E, et al. Clinical application of genomic profiling in AML. Nat Rev Clin Oncol. 2016;13(6):341–355.
26. Nam AS, Chaligne R, Landau DA. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics. Nat Rev Genet. 2021;22(1):3–18.
27. Schurer A, Glushakow-Smith SG, Gritsman K. Targeting chromatin modifying complexes in acute myeloid leukemia. Stem Cells Transl Med. 2025 Feb 11;14(2):szae089. doi: 10.1093/stcltm/szae089. PMID: 39607901; PMCID: PMC11878770.
28. Fundytus A, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol. 2021 Oct;22(10):1367-1377. doi: 10.1016/S1470-2045(21)00463-0. Epub 2021 Sep 21. PMID: 34560006; PMCID: PMC8476341.
29. Akter, T., Ghosh, K. P., Rabbi, A., Rahman, M. M., Rume, M. J. (2024). A Machine Learning Approach to Predict Blood Cancer from Patients' Symptoms and Blood Images. Research Square (Research Square). https://doi.org/10.21203/rs.3.rs-4809690/v1.
